Antares Pharma — Jefferies 2018 Global Healthcare Conference
24 slides from Antares Pharma's conference presentation, Nov 15, 2018

Slide 1: Jefferies 2018 Global Healthcare Conference
NASDAQ: ATRS Jefferies 2018 Global Healthcare Conference November 15, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1

Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate

Slide 3: Antares Pharma
Antares Pharma A Growing Specialty Pharmaceutical Company with 2017 Revenue of $54.5 Million – 2018 year-to-date revenue through September 30 of $44.7 Million Anticipated full year 2018 revenue to be in a range of $60-$65 million – a range of 10% - 20% increase over 2017 revenue An Innovative Leader

Slide 4: Antares Pharma – 2018 Significant Achievements
Antares Pharma – 2018 Significant Achievements February approval of AMAG’s Makena® auto injector product utilizing QuickShot® Device August approval of Teva’s therapeutically equivalent generic EpiPen® August Alliance Business Transaction Announced – Pfizer Rescue Pen XYOSTED™ NDA Approved September

Slide 5: Proprietary and Partnered Commercial Products
NASDAQ: ATRS Proprietary and Partnered Commercial Products

Slide 6: A New Choice in the Management of Testosterone Deficiency
A NEW CHOICE in the Management of TESTOSTERONE DEFICIENCY The first and only weekly auto-injector for TRT

Slide 7: XYOSTED Product Features
PRODUCT FEATURES Easy to use and store at room temperature Fine (27-gauge) needle allows for rapid subcutaneous delivery of sesame oil solution (~10 seconds) Locking needle guard hides needle before, during, and after administration and reduces risk of needle stick injuries TE, testosterone enanthat

Slide 8: Ctrough Stable For Weeks
Ctrough Stable For 52 Weeks Mean Ctrough (ng/dL) over 52 week “003” study 6 12 18 26 38 52 Week 1, pre-dose QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL at 12 weeks Orange lines represent the defined range of 300 – 1100 ng/dL . .

Slide 9: Easy up-down titration
Easy up-down titration If TT C trough is Dose should 650 ng/dL Decrease by 25 mg (to 50 mg/ weekly) 350 ng/dL Increase by 25 mg (to 100mg/weekly) 350 ng/dL and 650 ng/dL Be maintained Dose adjustments based upon pre-dose testosterone levels (samples measured 7 days after most recent dose) that are o

Slide 10: Testosterone Replacement Market: Jan 2015 – Sept 2018
Testosterone Replacement Market: Jan 2015 – Sept 2018 Retail Prescriptions 2016 2015 2018 Symphony Health Solutions: Phast IDV – Total 2017 TRx’s 6.5M

Slide 11: XYOSTED Commercial Launch Planning Underway
XYOSTED™ Commercial Launch Planning Underway Key Next Steps: Recruitment of ~60 sales representatives with onboarding scheduled for late November Finalize Payer Access Strategy and initiate contracting with large plans and PBM’s Finalize all Marketing Assets and Activities Distribution Strategy and

Slide 12: ATRS Proprietary/Commercial Products
ATRS Proprietary/Commercial Products OTREXUP® (methotrexate) injection Sumatriptan Injection USP (Approved October 2013 – VIBEX® Device) (Approved December 2015 - VIBEX® Device)

Slide 13: Makena hydroxyprogesterone caproate injection
Makena® hydroxyprogesterone caproate injection Utilizing ATRS QuickShot® Device Subcutaneous injection Intramuscular injection Efficient Discreet Administration friendly ü ü ü Makena® - Used to Reduce the Risk of Preterm Birth in Certain At-Risk Women Approved February ‘18 - ATRS supplies packaged p

Slide 14: Teva's Epinephrine Injection USP Approved Utilizing ATRS VIBEX Device
Teva’s Epinephrine Injection USP Approved Utilizing ATRS VIBEX® Device Teva’s generic EpiPen® was approved August 16, 2018 Therapeutically equivalent and fully substitutable at the pharmacy Antares received a $2 million milestone payment from Teva upon approval Pre-launch devices have been shipped t

Slide 15: Alliance Business Pipeline
NASDAQ: ATRS Alliance Business Pipeline

Slide 16: Alliance Business Pipeline
Alliance Business Pipeline Exenatide Teriparatide Teva filed against Byetta® (exenatide) and they are working through the regulatory approval process using the ANDA pathway. ATRS believes Teva has first to file status and 180 days of marketing exclusivity, launch pending approval Teva filed against

Slide 17: ATRS – Building Momentum For 2019
ATRS – Building Momentum For 2019 XYOSTED™ FDA approved - Planned 4th quarter 2018 launch Growth of AMAG’s Makena® SC auto injector product Expected 4th quarter 2018 launch of Teva’s generic EpiPen® Progress on development partnership with Pfizer for rescue pen Addition to pipeline of a strategic ne

Slide 18: Jefferies 2018 Global Healthcare Conference
NASDAQ: ATRS Jefferies 2018 Global Healthcare Conference November 15, 2018 Robert F. Apple President and Chief Executive Officer

Slide 19: Appendix I XYOSTED Important Safety Information
Appendix I XYOSTED™ Important Safety Information

Slide 20: Important Safety Information
Important Safety Information XYOSTED™ INDICATIONS AND USAGE XYOSTED™ (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or

Slide 21: Important Safety Information
Important Safety Information CONTRAINDICATIONS XYOSTED™ is contraindicated in: Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with known hyper

Slide 22: Important Safety Information
Important Safety Information If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning th

Slide 23: Important Safety Information
Important Safety Information Gynecomastia—Gynecomastia may develop and may persist in patients being treated for hypogonadism. Sleep Apnea—Treatment with testosterone products, including XYOSTED™, may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chro

Slide 24: Important Safety Information
Important Safety Information USE IN SPECIFIC POPULATIONS Pregnancy—XYOSTED™ is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. Exposure of a female fetus to an
Source: SEC EDGAR · 8-K filed Nov 15, 2018
More decks from Antares Pharma Inc
Investor Presentation (March 2022)25 slides · Mar 7, 2022
Investor Presentation (January 2022)25 slides · Jan 12, 2022
Investor Presentation (August 2021)28 slides · Aug 18, 2021
Investor Presentation (June 2021)27 slides · Jun 1, 2021
Investor Presentation (March 2021)28 slides · Mar 5, 2021
Investor Presentation (January 2021)28 slides · Jan 11, 2021